Newronika
PrivateLast Round
Series B
Feb 13, 2025
Total Funding Raised
$27.85M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Newronika operates in Healthcare & Life Sciences and is based in Milan. Its latest recorded funding round was a Series B round in February 2025.
Newronika is a medtech company that develops adaptive deep brain stimulation technology to treat neurological disorders such as Parkinson's disease.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Medical AI, Biotechnology, Clinical Trials, Health IoT
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Newronika Comparables
Compare Newronika with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aleva Neurotherapeutics | 82% | |
| Medtronic | 82% | |
| 景昱医疗科技（苏州）股份有限公司 | 76% |
For institutional investors. Book with your work email.
Newronika Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 13, 2025 | ||||
| VC Round | Jan 22, 2024 | ||||
| Grant | Mar 8, 2023 | ||||
| Series A | Sep 26, 2019 | ||||
| Seed | Jun 14, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Newronika Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| TNBT Capital | Series B |
| European Innovation Council Fund | Grant |
| Innogest Capital | Series A, Series B |
| Indaco Venture Partners SGR | Series A, Series B |
| F3F | Series A, Series B |
| Origine SGR | Series B, Seed |
| Wille Finance AG | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 76% MoM.
- Feb 13, 2025
$14.1M round completed.
For institutional investors. Book with your work email.
Newronika Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Newronika's valuation, stock price, and market status.
Is Newronika a public or private company?
Newronika is a private company.
What is the current stock price of Newronika?
Newronika is a private company, so its shares have no public market price. Caplight tracks Newronika's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Newronika worth (valuation)?
Valuation information for Newronika is not publicly available.
Can I buy Newronika stock?
Newronika shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Newronika's last funding round?
Newronika's most recent funding round was Series B on February 13, 2025.
Who are the main investors in Newronika?
Key investors in Newronika include Origine SGR, Omnes Capital, ENEA-Tech and Biomedical Foundation, EIC Fund.
Will Newronika IPO soon?
No public IPO plans have been announced for Newronika.
How can I track Newronika secondary market activity?
Caplight tracks bids, offers, and trades in Newronika's shares on secondary markets.